Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 62% Improvement Relative Risk Kadnur et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 358 patients in India (April - June 2020) Fewer cases with HCQ (p=0.01) Kadnur et al., J. Family Medicine and Primary Care, doi:10.4103/jfmpc.jfmpc_1177_21 Favors HCQ Favors control
Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India
Kadnur et al., Journal of Family Medicine and Primary Care, doi:10.4103/jfmpc.jfmpc_1177_21
Kadnur et al., Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from.., Journal of Family Medicine and Primary Care, doi:10.4103/jfmpc.jfmpc_1177_21
Jul 2020   Source   PDF  
  All Studies   Meta
Prophylaxis study with 334 low-risk healthcare workers in India, showing significantly lower risk of cases with treatment. Symptomatic patients received PCR results, but only some asymptomatic patients did, so there may have been additional asymptomatic cases. There were no severe adverse events.
risk of case, 62.3% lower, RR 0.38, p = 0.01, treatment 10 of 258 (3.9%), control 15 of 100 (15.0%), NNT 9.0, odds ratio converted to relative risk, multivariate logistic regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kadnur et al., 22 Jul 2020, prospective, India, peer-reviewed, mean age 31.2, 16 authors, study period 23 April, 2020 - 11 June, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Original Article Hydroxychloroquine pre‑exposure prophylaxis for COVID‑19 among healthcare workers: Initial experience from India Harshith B. Kadnur1, Anivita Aggarwal1, Manish Soneja1, Komal Singh1, Ankit Mittal1, Neeraj Nischal1, Praveen Tirlangi1, Adil Rashid Khan1, Devashish Desai1, Ankesh Gupta1, Arvind Kumar1, Pankaj Jorwal1, Ashutosh Biswas1, Ravindra Mohan Pandey2, Naveet Wig1, Randeep Guleria3 Departments of 1Medicine, 2Biostatistics and 3Pulmonary Medicine and Sleep Disorder, All India Institute of Medical Sciences, New Delhi, India A bstract Background: Hydroxychloroquine (HCQ) had generated considerable interest for coronavirus disease 2019 (COVID‑19) prophylaxis. We conducted a prospective observational study at a tertiary care hospital in India, with dedicated COVID‑19 care facilities. Objectives: Primary objective was incidence of adverse effects, secondary objective being efficacy in preventing COVID‑19. Methods: Healthcare workers were recruited and grouped based on voluntary HCQ prophylaxis as per national guidelines. Side effects in HCQ group were graded in accordance with national cancer institute-common terminology criteria for adverse events (NCI‑CTCAE) version 5.0. At 3–7‑week follow‑up, groups were compared for COVID‑19 exposure, symptoms development and severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) RT‑PCR results. Results: Among 358 participants recruited, 216 (60.3%) were males and mean age was 31.2 ± 6.6 years. Chemoprophylaxis was initiated by 258 (72%) participants. After loading dose, 7 (2.7%) reported grade 2 and 1 (0.4%) grade 3 adverse effects. Discontinuation of HCQ due to side effects was reported in 11 (4.3%) participants. Electrocardiogram was done by 50 (19.4%) participants on HCQ; no abnormalities were noted. A total of 106 (41%) among those taking and 63 (63%) among those not taking HCQ were tested for SARS‑CoV‑2 due to influenza‑like illness or significant exposure. Among all participants, 25 (6.9%, 95% confidence interval [CI] 4.3–9.6) developed COVID‑19 during the study period. In the group taking HCQ, 10 (3.9%) tested positive compared to 15 (15%) in the group not taking HCQ (P < 0.001). Odds ratio with HCQ intake was 0.34 (95% CI 0.13–0.83, P = 0.01) and the number needed to treat was 12. Conclusion: HCQ is safe at the recommended dose for pre‑exposure prophylaxis of COVID‑19. Keywords: COVID‑19, healthcare workers, hydroxychloroquine, pre‑exposure prophylaxis, SARS‑CoV‑2
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop